Table 3. Characteristics and outcomes of 15 patients who received treatment for relapse or progression after nonmyeloablative UCB transplantation.
Patient | Histological Diagnosis |
Disease status at UCBT |
Number of Prior Therapies |
Time to relapse/ progression (days) |
Time to acute GVHD (days) |
Chimerism at the time of relapse/ progression |
Treatment at relapse/progression |
Time from relapse/ progression to treatment (months) |
Response to treatment |
Outcome |
---|---|---|---|---|---|---|---|---|---|---|
1 | Diffuse Large cell B-Cell | Partial Remission | 3 | 104 | 19 | 100% | taper immunosuppression* + rituximab† | < 1 | CR | Alive |
2 | Diffuse Large cell B-Cell | Partial Remission | 3§ | 6 | 51 | 82% | taper immunosuppression*,+ rituximab† | < 1 | PROG | Dead |
3 | Diffuse Large cell B-Cell | Partial Remission | 6 | 164 | 30 | 100% | rituximab† | 5 | CR | Alive |
4 | Diffuse Large cell B-Cell | Partial Remission | 3 | 120 | 31 | 100% | taper immunosuppression* + rituximab† | 5 | CR | Alive |
5 | Diffuse Large cell B-Cell | Partial Remission | 2§ | 21 | No | 100% | taper immunosuppression* + rituximab† | < 1 | PROG | Dead |
6 | Diffuse Large cell B-Cell | Partial Remission | 2 | 21 | 63 | NA | rituximab† + radiotherapy¶ | 3 | PROG | Dead |
7 | Diffuse Large cell B-Cell | Chemotherapy Refractory | 3 | 211 | No | 100% | taper immunosuppression* + rituximab† | 5 | CR | Alive |
8 | Mantle cell lymphoma | Chemotherapy Refractory | 2§ | 100 | No | 100% | taper immunosuppression* + chemotherapy + radio-immunotherapy | 2 | CR | Alive |
9 | Large cell T-Cell | Partial Remission | 2 | 90 | 35 | 97% | radiotherapy | 1 | PROG | Dead |
10 | Anaplastic T Cell | Partial Remission | 3 | 236 | No | 100% | taper immunosuppression* | < 1 | CR | Alive |
11 | Follicular B-cell | Partial Remission | 8 | 55 | 72 | 91% | rituximab† | 6 | CR | Alive |
12 | Follicular B-cell | Complete Remission | 4 | 188 | No | 100% | taper immunosuppression* + rituximab† | 3 | CR | Alive |
13 | Follicular B-cell | Partial Remission | 4 | 42 | 67 | 100% | taper immunosuppression* | 1 | PROG | Dead |
14 | Hodgkin Lymphoma | Complete Remission | 4§ | 106 | No | NA | taper immunosuppression* + chemotherapy + radiotherapy | 18± | CR | Alive |
15 | Hodgkin Lymphoma | Partial Remission | 9 | 88 | 15 | 100% | taper immunosuppression* + chemotherapy + radiotherapy | 6 | PROG | Dead |
UCBT, umbilical cord blood transplantation; GVHD, graft-vs.-host- disease; CR, complete remission; PROG, progression
Taper of cyclosporine A and/or steroids started one to four weeks of diagnosis of relapse/progression.
Rituximab was dosed at 375 mg/m2/week for 4 weeks
Patient who underwent prior autologous transplant
Interval to last salvage therapy
Palliative intent radiation therapy